BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 8422222)

  • 21. Panic disorder: long-term pharmacotherapy and discontinuation.
    Rickels K; Schweizer E
    J Clin Psychopharmacol; 1998 Dec; 18(6 Suppl 2):12S-18S. PubMed ID: 9872708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response.
    Rosenberg R; Bech P; Mellergård M; Ottosson JO
    Acta Psychiatr Scand Suppl; 1991; 365():46-52. PubMed ID: 1862734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug treatment of panic disorder: early response to treatment as a predictor of final outcome.
    Albus M; Lecrubier Y; Maier W; Buller R; Rosenberg R; Hippius H
    Acta Psychiatr Scand; 1990 Nov; 82(5):359-65. PubMed ID: 2281806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis.
    Boyer W
    Int Clin Psychopharmacol; 1995 Mar; 10(1):45-9. PubMed ID: 7622804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
    Lesser IM; Lydiard RB; Antal E; Rubin RT; Ballenger JC; DuPont R
    Am J Psychiatry; 1992 Nov; 149(11):1556-62. PubMed ID: 1415824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment.
    Deltito JA; Argyle N; Klerman GL
    J Clin Psychiatry; 1991 Mar; 52(3):121-7. PubMed ID: 2005075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
    Greenblatt DJ; Harmatz JS; Shader RI
    Arch Gen Psychiatry; 1993 Sep; 50(9):715-22. PubMed ID: 8357297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure.
    Başoğlu M; Marks IM; Kiliç C; Swinson RP; Noshirvani H; Kuch K; O'Sullivan G
    Br J Psychiatry; 1994 May; 164(5):647-52. PubMed ID: 7921715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects.
    Pecknold JC; Swinson RP; Kuch K; Lewis CP
    Arch Gen Psychiatry; 1988 May; 45(5):429-36. PubMed ID: 3282479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure.
    Cox BJ; Endler NS; Lee PS; Swinson RP
    J Behav Ther Exp Psychiatry; 1992 Sep; 23(3):175-82. PubMed ID: 1487535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings.
    Mavissakalian MR; Perel JM
    Arch Gen Psychiatry; 1989 Feb; 46(2):127-31. PubMed ID: 2643933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diazepam versus alprazolam for the treatment of panic disorder.
    Noyes R; Burrows GD; Reich JH; Judd FK; Garvey MJ; Norman TR; Cook BL; Marriott P
    J Clin Psychiatry; 1996 Aug; 57(8):349-55. PubMed ID: 8752017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo.
    Cassano GB; Toni C; Petracca A; Deltito J; Benkert O; Curtis G; Hippius H; Maier W; Shera D; Klerman G
    Eur Neuropsychopharmacol; 1994 Mar; 4(1):47-53. PubMed ID: 8204996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM
    Arch Gen Psychiatry; 1999 Sep; 56(9):821-7. PubMed ID: 12884888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia].
    León CA; De Arango MV; Arevalo W; Calvo A; Montoya A; León A
    Acta Psiquiatr Psicol Am Lat; 1990; 36(1-2):59-72. PubMed ID: 2073024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine.
    Klein E; Colin V; Stolk J; Lenox RH
    Am J Psychiatry; 1994 Dec; 151(12):1760-6. PubMed ID: 7977882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
    Mavissakalian MR; Perel JM
    Am J Psychiatry; 1995 May; 152(5):673-82. PubMed ID: 7726306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary depression in panic disorder: an indicator of severity with a weak effect on outcome in alprazolam and imipramine treatment.
    Rosenberg R; Bech P; Mellergård M; Ottosson JO
    Acta Psychiatr Scand Suppl; 1991; 365():39-45. PubMed ID: 1862733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of the Cross-National Collaborative Panic Study.
    Klerman GL
    Arch Gen Psychiatry; 1988 May; 45(5):407-12. PubMed ID: 3282477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
    Lydiard RB; Lesser IM; Ballenger JC; Rubin RT; Laraia M; DuPont R
    J Clin Psychopharmacol; 1992 Apr; 12(2):96-103. PubMed ID: 1573046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.